ijms-logo

Journal Browser

Journal Browser

MicroRNAs as Biomarkers in Chronic Diseases

Special Issue Editor

Center for Primary Health Care Research, Department of Clinical Sciences, Malmö Lund University, Lund, Sweden
Interests: the discovery of circulating biomarkers

Special Issue Information

Dear Colleagues,

MicroRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression, have become central to biomedical research. Their significance was highlighted by the 2024 Nobel Prize in Physiology or Medicine, awarded for pioneering work in miRNA biology. miRNAs are essential regulators of key biological processes, and their dysregulation has been linked to the development and progression of numerous diseases.

Since the discovery of circulating miRNAs in 2008, these molecules have gained significant attention as promising non-invasive biomarkers. Found in various body fluids—including blood, saliva, and urine—miRNAs are remarkably stable, protected by their association with proteins, lipids, or encapsulation within exosomes. This stability, even under harsh conditions such as low pH or repeated freeze–thaw cycles, makes miRNAs particularly attractive for diagnostic applications.

Circulating miRNAs act not only as biomarkers but also as mediators of intercellular communication. Their expression patterns reflect physiological and pathological states, making them valuable tools for disease prediction, early diagnosis, prognosis, and the monitoring of treatment responses. For instance, liver-specific miRNAs such as miR-122 and miR-192 are released into the bloodstream during hepatic injury, demonstrating tissue specificity and clinical utility.

This Special Issue, ‘MicroRNAs as Biomarkers in Chronic Diseases,’ aims to highlight the latest advances in the use of miRNAs across a spectrum of chronic diseases. We welcome original research articles, comprehensive reviews, and novel perspectives that explore the role of miRNAs in disease risk assessment, diagnosis, prognosis, and therapeutic monitoring. Topics may include—but are not limited to—cancers, cardiovascular diseases, and psychiatric conditions.

We look forward to contributions that will help shape the future of miRNA-based diagnostics and precision medicine.

Dr. Xiao Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNA
  • biomarker
  • chronic diseases
  • cancer
  • cardiovascular diseases
  • psychiatric conditions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 2331 KB  
Article
Circulating miR-16 as an Early Biomarker of Subclinical Myocardial Strain Impairment in Pediatric Primary Hypertension
by Michał Szyszka, Radosław Pietrzak, Klaudia Obsznajczyk, Karolina Skubisz, Ceren Eyileten and Piotr Skrzypczyk
Int. J. Mol. Sci. 2026, 27(6), 2806; https://doi.org/10.3390/ijms27062806 - 20 Mar 2026
Cited by 1 | Viewed by 361
Abstract
The role of circulating microRNAs in the pathophysiology of cardiac remodeling in primary hypertension (PH) remains incompletely understood. Left ventricular global longitudinal strain (LV GLS) is a sensitive marker of subclinical systolic dysfunction and can be used to monitor early cardiac involvement in [...] Read more.
The role of circulating microRNAs in the pathophysiology of cardiac remodeling in primary hypertension (PH) remains incompletely understood. Left ventricular global longitudinal strain (LV GLS) is a sensitive marker of subclinical systolic dysfunction and can be used to monitor early cardiac involvement in cardiovascular and renal diseases. To the best of our knowledge, this is the first study to demonstrate an association between circulating miR-16 and LV GLS in children. The study aimed to evaluate the expression levels of miR-16-5p, -21-5p, -27a-3p, -27b-3p, -133a-3p, and -145-5p in untreated children with PH and examine their associations with LV GLS. 50 children with PH and 57 normotensive controls were evaluated for circulating microRNA expression levels and echocardiographic parameters, including LV GLS. Comprehensive anthropometric, biochemical, blood pressure, and arterial indices were also assessed. Among the analyzed microRNAs, miR-16-5p exhibited a positive association with LV GLS (R = 0.305, p = 0.031), whereas miR-27b-3p demonstrated a negative association (R = −0.330, p < 0.001). Compared with controls, hypertensive children exhibited significantly higher (i.e., less negative) LV GLS (r = 0.29, p = 0.002), indicating early systolic dysfunction occurring already at an early stage of the disease. In conclusion, these findings support the idea that specific microRNAs might play a differential role in early myocardial functional alterations in pediatric PH. Higher miR-16 expression levels may be associated with impaired myocardial deformation, potentially reflecting its involvement in early maladaptive myocardial remodeling. Furthermore, LV GLS may represent a sensitive and clinically informative marker of early myocardial dysfunction beyond traditional echocardiographic parameters in this population. Full article
(This article belongs to the Special Issue MicroRNAs as Biomarkers in Chronic Diseases)
Show Figures

Figure 1

Back to TopTop